-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
HIV-1-inhibitor-13
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/hiv-1-inhibitor-13.gif)
| Category | Human immunodeficiency Virus (HIV) |
| Description | HIV-1 inhibitor-13 (compound 16c) is a orally active and potent HIV-1 non nucleoside reverse transcriptase inhibitor (NNRTI), with IC50 of 0.14 μM (HIV-1 RT). HIV-1 inhibitor-13 shows activity against a panel of HIV-1 resistant strains, with EC50 values of 2.85-18.0 nM. |
Product Information
| Synonyms | HIV-1 inhibitor-13|HY-144112|CS-0376554 |
| Molecular Weight | 524.61 |
| Molecular Formula | C30H32N6O3 |
| Canonical SMILES | CC1=CC(=CC(=C1OC2=NC(=NC3=C2COC3)NC4CCN(CC4)CC5=CC=C(C=C5)C(=O)N)C)C=CC#N |
| Purity | ≥98% (HPLC) |
| Solubility | 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 878 |
| Exact Mass | 524.25358890 |
| In Vivo | HIV-1 inhibitor-13 (compound 16c) (SD rats; 2 mg/kg, IV; 10 mg/kg, PO; once) exhibits favorable pharmacokinetic profiles (F = 32.1% and T1/2 = 0.88 and 1.05 h, respectively). HIV-1 inhibitor-13 (Kunming mice, 2000 mg/kg, PO, once) shows safety in Kunming mice (LD50 > 2000 mg/kg). |
| Target | HIV-1 (WT): 2.85 ± 1.1 nM (EC50) |
| XLogP3-AA | 3.5 |
